Synergistic anticancer effects of vorinostat and epigallocatechin-3-gallate against HuCC-T1 human cholangiocarcinoma cells

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Kwak, Tae Won ^a   Kim, Do Hyung ^a   Chung, Chung Wook ^a   Lee, Hye Myeong ^a   Kim, Cy Hyun ^a   Jeong, Young Il ^a   Kang, Dae Hwan ^a  

^a Pusan National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; EPIGALLOCATECHIN GALLATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; VASCULOTROPIN; VORINOSTAT;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; TUMOR INVASION; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 84880213500     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/185158     Document Type: Article

References (46)

1. Lim J. H., Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. American Journal of Roentgenology 2003 181 3 819 827 2-s2.0-0041508684
2. Sandhu D. S., Roberts L. R., Diagnosis and management of cholangiocarcinoma. Current Gastroenterology Reports 2008 48 43 52
3. Singh P., Patel T., Advances in the diagnosis, evaluation and management of cholangiocarcinoma. Current Opinion in Gastroenterology 2006 22 3 294 299 2-s2.0-33746261414 10.1097/01.mog.0000218967.60633.64
4. Khan S. A., Taylor-Robinson S. D., Toledano M. B., Beck A., Elliott P., Thomas H. C., Changing international trends in mortality rates for liver, biliary and pancreatic tumours. Journal of Hepatology 2002 37 6 806 813 2-s2.0-0036892977 10.1016/S0168-8278(02)00297-0
5. Patel T., Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001 33 6 1353 1357 2-s2.0-0034982536 10.1053/jhep.2001.25087
6. Khan S. A., Thomas H. C., Davidson B. R., Taylor-Robinson S. D., Cholangiocarcinoma. Lancet 2005 366 9493 1303 1314 2-s2.0-26244441537 10.1016/S0140-6736(05)67530-7
7. Sriwanitchrak P., Viyanant V., Chaijaroenkul W., Srivatanakul P., Gram H. R., Eursiddhichai V., Na-Bangchang K., Proteomics analysis and evaluation of biomarkers for detection of cholangiocarcinoma. Asian Pacific Journal of Cancer Prevention 2011 12 6 1503 1510 2-s2.0-84855415036
8. Sirica A. E., Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 2005 41 1 5 15 2-s2.0-11244335567 10.1002/hep.20537
9. Blechacz B. R. A., Gores G. J., Cholangiocarcinoma. Clinics in Liver Disease 2008 12 1 131 150 2-s2.0-38549129833 10.1016/j.cld.2007.11.003
10. Bhuiya M. R., Nimura Y., Kamiya J., Kondo S., Fukata S., Hayakawa N., Shionoya S., Clinicopathologic studies on perineural invasion of bile duct carcinoma. Annals of Surgery 1992 215 4 344 349 2-s2.0-0026544943
11. Shen F. Z., Zhang B. Y., Feng Y. J., Jia Z. X., An B., Liu C. C., Deng X. Y., Kulkarni A. D., Lu Y., Current research in perineural invasion of cholangiocarcinoma. Journal of Experimental & Clinical Cancer Research 2010 29 24
12. Chung K.-D., Jeong Y.-I., Chung C.-W., Kim D. H., Kang D. H., Anti-tumor activity of all-trans retinoic acid-incorporated glycol chitosan nanoparticles against HuCC-T1 human cholangiocarcinoma cells. International Journal of Pharmaceutics 2012 422 1-2 454 461 2-s2.0-84655164879 10.1016/j.ijpharm.2011.10. 057
13. Richon V. M., Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. British Journal of Cancer 2006 95 1 S2 S6 2-s2.0-33845615494 10.1038/sj.bjc.6603463
14. Takada Y., Gillenwater A., Ichikawa H., Aggarwal B. B., Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor- B activation. Journal of Biological Chemistry 2006 281 9 5612 5622 2-s2.0-33646851955 10.1074/jbc.M507213200
15. Xu W. S., Parmigiani R. B., Marks P. A., Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007 26 37 5541 5552 2-s2.0-34547864236 10.1038/sj.onc.1210620
16. Gui C.-Y., Ngo L., Xu W. S., Richon V. M., Marks P. A., Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proceedings of the National Academy of Sciences of the United States of America 2004 101 5 1241 1246 2-s2.0-0842277812 10.1073/pnas.0307708100
17. Deroanne C. F., Bonjean K., Servotte S., Devy L., Colige A., Clausse N., Blacher S., Verdin E., Foidart J.-M., Nusgens B. V., Castronovo V., Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002 21 3 427 436 2-s2.0-0037122875 10.1038/sj/onc/1205108
18. Shankar S., Ganapathy S., Srivastava R. K., Green tea polyphenols: biology and therapeutic implications in cancer. Frontiers in Bioscience 2007 12 13 4881 4899 2-s2.0-34547680062 10.2741/2435
19. Liao S., Umekita Y., Guo J., Kokontis J. M., Hiipakka R. A., Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Letters 1995 96 2 239 243 2-s2.0-0029124096 10.1016/0304-3835(95)03948-V
20. Thangapazham R. L., Singh A. K., Sharma A., Warren J., Gaddipati J. P., Maheshwari R. K., Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Letters 2007 245 1-2 232 241 2-s2.0-33845636448 10.1016/j.canlet.2006.01.027
21. Das A., Banik N. L., Ray S. K., Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes. Cancer 2010 116 1 164 176 2-s2.0-74549127500 10.1002/cncr.24699
22. Qiao Y., Cao J., Xie L., Shi X., Cell growth inhibition and gene expression regulation by (-)-epigallocatechin-3-gallate in human cervical cancer cells. Archives of Pharmacal Research 2009 32 9 1309 1315 2-s2.0-70349558215 10.1007/s12272-009-1917-3
23. Philips B. J., Coyle C. H., Morrisroe S. N., Chancellor M. B., Yoshimura N., Induction of apoptosis in human bladder cancer cells by green tea catechins. Biomedical Research 2009 30 4 207 215 2-s2.0-70349397276 10.2220/biomedres.30. 207
24. Min N. Y., Kim J.-H., Choi J.-H., Liang W., Ko Y. J., Rhee S., Bang H., Ham S. W., Park A. J., Lee K.-H., Selective death of cancer cells by preferential induction of reactive oxygen species in response to (-)-epigallocatechin-3-gallate. Biochemical and Biophysical Research Communications 2012 421 1 91 97 2-s2.0-84860320529 10.1016/j.bbrc.2012.03.120
25. Sartor L., Pezzato E., Donà M., Dell'Aica I., Calabrese F., Morini M., Albini A., Garbisa S., Prostate carcinoma and green tea: (-)Epigallocatechin-3-gallate inhibits inflammation-triggered MMP-2 activation and invasion in murine tramp model. International Journal of Cancer 2004 112 5 823 829 2-s2.0-7244243792 10.1002/ijc.20496
26. Benelli R., Venè R., Bisacchi D., Garbisa S., Albini A., Anti-invasive effects of green tea polyphenol epigallocatechin-3-gallate (EGCG), A natural inhibitor of metallo and serine proteases. Biological Chemistry 2002 383 1 101 105 2-s2.0-0036005963 10.1515/BC.2002.010
27. Baliga M. S., Meleth S., Katiyar S. K., Growth inhibitory and antimetastatic effect of green tea polyphenols on metastasis-specific mouse mammary carcinoma 4T1 cells in vitro and in vivo systems. Clinical Cancer Research 2005 11 5 1918 1927 2-s2.0-16344365082 10.1158/1078-0432.CCR-04-1976
28. Lee Y. H., Kwak J., Choi H. K., Choi K. C., Kim S., Lee J., Jun W., Park H. J., Yoon H. G., EGCG suppresses prostate cancer cell growth modulating acetylation of androgen receptor by anti-histone acetyltransferase activity. International Journal of Molecular Medicine 2012 30 69 74
29. Okabe H., Beppu T., Hayashi H., Ishiko T., Masuda T., Otao R., Horlad H., Jono H., Ueda M., Shinriki S., Ando Y., Baba H., Hepatic stellate cells accelerate the malignant behavior of cholangiocarcinoma cells. Annals of Surgical Oncology 2011 18 4 1175 1184 2-s2.0-79955820751 10.1245/s10434-010- 1391-7
30. Chandra J., Miller C. P., Singh M. M., Rivera-Del Valle N., Manton C. A., Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. Journal of Biomedicine and Biotechnology 2011 2011 17 2-s2.0-80052653226 10.1155/2011/514261 514261
31. Brodská B., Holoubek A., Generation of reactive oxygen species during apoptosis induced by DNA-damaging agents and/or histone deacetylase inhibitors. Oxidative Medicine and Cellular Longevity 2011 2011 7 2-s2.0-81555220893 10.1155/2011/253529 253529
32. Kelly W. K., Richon V. M., O'Connor O., Curley T., MacGregor-Curtelli B., Tong W., Klang M., Schwartz L., Richardson S., Rosa E., Drobnjak M., Cordon-Cordo C., Chiao J. H., Rifkind R., Marks P. A., Scher H., Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clinical Cancer Research 2003 9 10 I 3578 3588 2-s2.0-12444321545
33. Kelly W. K., O'Connor O. A., Krug L. M., Chiao J. H., Heaney M., Curley T., MacGregore-Cortelli B., Tong W., Secrist J. P., Schwartz L., Richardson S., Chu E., Olgac S., Marks P. A., Scher H., Richon V. M., Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Journal of Clinical Oncology 2005 23 17 3923 3931 2-s2.0-21244464349 10.1200/JCO.2005.14.167
34. O'Connor O. A., Heaney M. L., Schwartz L., Richardson S., Willim R., MacGregor-Cortelli B., Curly T., Moskowitz C., Portlock C., Horwitz S., Zelenetz A. D., Frankel S., Richon V., Marks P., Kelly W. K., Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. Journal of Clinical Oncology 2006 24 1 166 173 2-s2.0-33644836549 10.1200/JCO.2005.01.9679
35. Luu T. H., Morgan R. J., Leong L., Lim D., McNamara M., Portnow J., Frankel P., Smith D. D., Doroshow J. H., Gandara D. R., Aparicio A., Somlo G., Wong C., A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California cancer consortium study. Clinical Cancer Research 2008 14 21 7138 7142 2-s2.0-58149242889 10.1158/1078-0432.CCR-08-0122
36. Blumenschein G. R. Jr., Kies M. S., Papadimitrakopoulou V. A., Lu C., Kumar A. J., Ricker J. L., Chiao J. H., Chen C., Frankel S. R., Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza ™ suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Investigational New Drugs 2008 26 1 81 87 2-s2.0-38149140216 10.1007/s10637-007-9075-2
37. An Z., Gluck C. B., Choy M. L., Kaufman L. J., Suberoylanilide hydroxamic acid limits migration and invasion of glioma cells in two and three dimensional culture. Cancer Letters 2010 292 2 215 227 2-s2.0-77951931604 10.1016/j.canlet.2009.12.006
38. Galanis E., Jaeckle K. A., Maurer M. J., Reid J. M., Ames M. M., Hardwick J. S., Reilly J. F., Loboda A., Nebozhyn M., Fantin V. R., Richon V. M., Scheithauer B., Giannini C., Flynn P. J., Moore D. F. Jr., Zwiebel J., Buckner J. C., Phase II trial of Vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. Journal of Clinical Oncology 2009 27 12 2052 2058 2-s2.0-65349141942 10.1200/JCO.2008.19.0694
39. Khan N., Mukhtar H., Cancer and metastasis: prevention and treatment by green tea. Cancer and Metastasis Reviews 2010 29 3 435 445 2-s2.0-77957590316 10.1007/s10555-010-9236-1
40. Liu J.-D., Chen S.-H., Lin C.-L., Tsai S.-H., Liang Y.-C., Inhibition of melanoma growth and metastasis by combination with (-)-epigallocatechin-3- gallate and dacarbazine in mice. Journal of Cellular Biochemistry 2001 83 4 631 642 2-s2.0-0035169315 10.1002/jcb.1261
41. Nihal M., Roelke C. T., Wood G. S., Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)-Epigallocatechin-3-Gallate (EGCG). Pharmaceutical Research 2010 27 6 1103 1114 2-s2.0-77953232497 10.1007/s11095-010-0054-5
42. Lang M., Henson R., Braconi C., Patel T., Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. Liver International 2009 29 5 670 677 2-s2.0-64749098018 10.1111/j.1478-3231. 2009.01984.x
43. Basu H. S., Mahlum A., Mehraein-Ghomi F., Kegel S. J., Guo S., Peters N. R., Wilding G., Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA). Cancer Chemotherapy and Pharmacology 2011 67 3 705 715 2-s2.0-79953788698 10.1007/s00280-010-1364-3
44. Li Y., Yuan Y.-Y., Meeran S. M., Tollefsbol T. O., Synergistic epigenetic reactivation of estrogen receptor- α (ER α) by combined green tea polyphenol and histone deacetylase inhibitor in ER α -negative breast cancer cells. Molecular Cancer 2010 9, article 274 2-s2.0-77957784810 10.1186/1476-4598-9-274
45. Choi K.-C., Myung G. J., Lee Y.-H., Joo C. Y., Seung H. K., Kang H.-B., Kim M.-J., Cha J.-H., Young J. K., Woo J. J., Jae M. L., Yoon H.-G., Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Research 2009 69 2 583 592 2-s2.0-58349094740 10.1158/0008-5472.CAN-08- 2442
46. Kim S. O., Kim M. R., (-)-Epigallocatechin 3-gallate inhibits invasion by inducing the expression of Raf kinase inhibitor protein in AsPC-1 human pancreatic adenocarcinoma cells through the modulation of histone deacetylase activity. International Journal of Oncology 2013 42 349 358